Insmed has evolved significantly over the years, but one thing that has remained unchanged is our commitment to patients. As we look toward the future, we are inspired by our vision to deliver life-altering therapies to small patient populations experiencing big health problems. Read on to learn more about some of the key moments that have shaped who Insmed is today.
Insmed is founded as a private company by Dr. Joseph Larner in Charlottesville, Va., to develop medicines to treat diabetes.
Transave is founded as a private company by Dr. Frank Pilkiewicz in Monmouth Junction, NJ, to develop inhaled pharmaceuticals for the treatment of lung diseases.
Insmed is incorporated in the Commonwealth of Virginia and becomes a public company (INSM) after acquiring Celtrix Pharmaceuticals in a reverse merger.
Transave pioneers the early development of an inhaled liposomal antibiotic, an advancement that will later enable the approval of the Company’s first therapy.
Insmed enters into a business combination with Transave, acquiring its late-stage candidate. The new company maintains the name Insmed.
Insmed receives Orphan Drug Designation, Qualified Infectious Disease Product designation, and Fast Track status for its lead product candidate.
Insmed enters into a worldwide license agreement with AstraZeneca for a product candidate, expanding the company’s rare disease pipeline.
Insmed opens an office in Utrecht, Netherlands, further expanding its presence to Europe.
Insmed submits a New Drug Application to the FDA for its lead product candidate.
Insmed is granted accelerated approval by the FDA for its first therapy.
Insmed opens an office in Tokyo, expanding its global presence to Japan.